Shared insight on the benefits and drawbacks of using tumor-infiltrating lymphocyte therapy for treatment of solid tumors, as compared to chimeric antigen receptor (CAR) T-cell therapy.

The phase 1 clinical trial is the second of Frontera’s trials to begin dosing in 2023.

Cartesian Therapeutics’ Descartes-08 will be administered as 6 weekly infusions and does not require preconditioning chemotherapy.

The professor at University Hospital Dresden discussed the positive safety profile of Unicar-T-CD123.

Decibel Therapeutics expects the trial for DB-OTO to begin in the first half of 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.